Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche to name a new CEO by March 2023

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 08, 2023 2:19pm

169 Views

Post# 35275084

RE:RE:RE:RE:RE:RE:Roche to name a new CEO by March 2023

Just remember that pelareorep will be used in combination with a Big Pharma's PD-(L)1 inhibitor and we don't yet know which one that will be. Neither does AN.

So rather than complicate potential ONCY's acquisition by a Big Pharma partner with an obscure "licensing agreement" that does not have an identified immune checkpoint inhibitor, AN prudently cleared the way for the Big Pharma to move on ONCY and then potentially deal with AN as a seperate matter, as determined by the Big Pharma acquirer of ONCY.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"